
Andrzej PieÅ, kowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5609020/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diagnostic Utility of Genetic and Immunohistochemical H3-3A Mutation Analysis in Giant Cell Tumour of Bone. International Journal of Molecular Sciences, 2022, 23, 969.	4.1	6
2	Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence. Cancers, 2022, 14, 2290.	3.7	12
3	Functional outcome of surgical treatment of adults with extremity osteosarcoma after megaprosthetic reconstruction—single-center experience. Journal of Orthopaedic Surgery and Research, 2019, 14, 346.	2.3	19
4	Long-term follow-up in adults with extremity osteosarcoma: comparison of different surgical procedures – single-center experience. Wspolczesna Onkologia, 2019, 23, 234-238.	1.4	1
5	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone – Multicenter analysis outside clinical trial. European Journal of Surgical Oncology, 2018, 44, 1384-1390.	1.0	70
6	IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma. Journal of Cancer, 2018, 9, 998-1005.	2.5	50
7	Treatment results of adult patients with primary bone tumours of the humerus with the use of the oncological modular endoprosthesis. Wspolczesna Onkologia, 2017, 3, 228-231.	1.4	1
8	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone. Oncology Letters, 2016, 12, 4312-4318.	1.8	28
9	Denosumab for treating giant cell tumor of bone. Expert Opinion on Orphan Drugs, 2015, 3, 1219-1229.	0.8	5
10	The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique. World Journal of Surgical Oncology, 2015, 13, 299.	1.9	10
11	Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone. Annals of Surgical Oncology, 2015, 22, 2860-2868.	1.5	142
12	Melanoma without a Detectable Primary Site with Metastases to Lymph Nodes. Dermatologic Surgery, 2010, 36, 868-876.	0.8	37